{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients with recurrent GBM were randomized into two groups"
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients with recurrent GBM"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Group A with unresectable disease received RO4929097 in a standard phase II design, while Group B with resectable disease received the drug before and after surgical resection."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the 6-month progression-free survival rate (PFS 6)"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was performed using [randomization method], with allocation concealment by [method]."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 47 patients were randomized, with 40 in Group A and 7 in Group B."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The PFS 6 was 4% (95% CI [confidence interval])"
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were reported in [number] patients, with [frequency and severity]."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "The trial was registered under [trial registration number]"
      },
      "Funding": {
        "score": 0,
        "evidence": "funded by [source of funding]."
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}